Nov 08, 2023 / 11:30AM GMT
Operator
Ladies and gentlemen, good day, and welcome to Q2 and H1 FY '24 Earnings Conference Call of Eris Lifesciences Limited. We have with us on the call today Mr. Amit Bakshi, Chairman and Managing Director; and Mr. V. Krishnakumar, Chief Operating Officer and Executive Director. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. V. Krishnakumar, Chief Operating Officer and Executive Director of the company. Thank you, and over to you, sir.
Krishnakumar Vaidyanathan - Eris Lifesciences Limited - Executive Director & COO
Thank you. Good afternoon, and welcome to our conference call for second quarter of FY '24. Earlier today, we have announced the execution of definitive agreement for the acquisition of Biocon's Nephrology and Dermatology businesses for a consideration of INR 366 crores, inclusive of working capital that will be conveyed to us as part of the business. This business is currently operating at a revenue run rate of INR 100 crores per annum. The key leadership and entire field
Q2 2024 Eris Lifesciences Ltd Earnings Call Transcript
Nov 08, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers